South Korean biopharma contract manufacturer Celltrion is considering acquiring US manufacturing sites to mitigate President ...

Novartis said Friday that last year was one of its 'strongest' financial performances in its history following a multiyear ...

Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...

Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP ...

Blackstone is raising a new life sciences fund, targeting at least $5B after initial $1.6B closing. Blackstone Life Sciences ...

More than two and a half years after the FDA rejected its migraine treatment, Axsome Therapeutics received an approval for ...

Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...

Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...

Sev­er­al months in­to a mul­ti­year quest to “rig­or­ous­ly pri­or­i­tize” its pipeline, Take­da is cut­ting a hand­ful of ...

A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far ...

Rinvoq to $31B amid Humira decline. Skyrizi hit $11.7B and Rinvoq $5.97B in 2024, while Humira fell to $9B from $14.4B in 2023.

Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...